[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639802":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":26,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":69,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"patients on Extracorporeal Membrane Oxygenation veno-venous",null,"major patients admitted to the general intensive care unit on Extracorporeal Membrane Oxygenation veno-venous",[13],"Other: blood draws",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"blood draws","Part of the biology data is used from the patient's routine blood tests. Additional blood samples are taken from an arterial catheter already in place. They are performed over 4 periods: one just before start ECMO and 3 under ECMO at 3-day intervals",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Baptiste COMPAGNON","CONTACT","5 61 32 27 99","+33","compagnon.b@chu-toulouse.fr",[27],{"facility":28,"status":10,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"UHToulouse","Toulouse","France","FR",{"type":33,"coordinates":34},"Point",[35,36],1.44367,43.60426,{"lat":36,"lon":35},[39],{"name":40,"role":22,"phone":10,"phoneExt":10,"email":10},"baptiste compagnon, PH",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100639802","platelets-and-extracorporeal-membrane-oxygenation-veno-venous-100639802",false,"NCT07580469","Platelets and Extracorporeal Membrane Oxygenation Veno-venous","Study of PLATelet Functions and Risk Factors for Hemorrhagic Complications in Patients on Extracorporeal Membrane Oxygenation Veno-venous: Prospective Monocentric Cohort","PLAT-VV-ECMO","Inclusion Criteria:\n\n* Adults aged ≥ 18 years\n* No objection to participation in the study, obtained from a relative or trusted person; if no relative is available, inclusion under emergency procedure (pending patient or relative non-opposition)\n* Patients requiring admission to the general intensive care unit of Hôpital Rangueil for venovenous ECMO\n* Equipped with an arterial catheter for blood sampling\n* Ability to undergo the 4 blood draws relevant to the study\n* Receiving therapeutic anticoagulation with unfractionated heparin\n* Enrolled in a social security program or equivalent\n* No measures for Limitation and Withdrawal of Therapy have been implemented\n\nExclusion Criteria:\n\n* Minors\n* Patients under court-appointed guardianship or conservatorship\n* Pregnant or breastfeeding women\n* Hematological disease (leukemia, lymphoma) or constitutional thrombocytopenia\n* Platelet transfusion within 7 days prior to enrollment\n* Indication for immediate emergency ECMO preventing blood sampling before placement\n* Post-cardiotomy\n* Patient on antiplatelet therapy\n* Severe thrombocytopenia \\\u003C50 G\u002FL\n* Other invasive mechanical support such as Impella®, intra-aortic balloon pump, or Left Ventricular Assist Device (LVAD)","ALL","18 Years",{"count":54,"type":55},40,"ESTIMATED","OBSERVATIONAL","In severe lung or heart disease, ExtraCorporeal Membrane Oxygenation (ECMO) may be used temporarily and can be responsible for major haemorrhagic complications. Thrombocytopenia and possibly thrombopathy promote bleeding. The primary objective is to characterize platelet dysfunction by aggregometry tests over time. Secondarily, investigators seek a correlation between haemorrhagic complications at day 10 and markers of platelet action and dysfunction; also, with the level of anticoagulation and inflammation by biomarkers.",[59,60,61,62],"Extracorporeal Membrane Oxygenation Complication","Hemorrhage","Blood Platelet Disorder","Thrombosis",[64,65,66,67,68],"VV-ECMO","Platelets","Thrombopathy","thrombo-haemorrhagic complications","thrombo-inflammation","NOT_YET_RECRUITING","2026-06-24",{"date":72,"type":73},"2026-06-29","ACTUAL",{"date":75,"type":55},"2026-09",{"date":77,"type":55},"2028-12-31",{"name":5,"class":6},1]